Vivos Therapeutics reported Q2 2024 revenue of $4.1 million, up 19% both YoY and QoQ, driven by increased product sales and higher VIP enrollment revenue. Operating expenses decreased 31% YoY, marking eight consecutive quarters of cost reduction. Gross margin improved to 65% from 62% in Q2 2023, while operating loss reduced by 57% YoY.The company secured a strategic $7.5 million equity investment from New Seneca Partners and launched a new marketing and distribution model through alliances with medical sleep specialists. A pilot program demonstrated strong patient preference, with 79% of newly diagnosed OSA patients choosing Vivos' oral appliance therapy over alternatives.As of June 2024, Vivos has treated over 45,000 patients worldwide and trained more than 2,000 dentists. The company received Medicare reimbursement approval for its CARE devices and maintains $6.9 million in cash with $6.3 million in stockholders' equity. Management anticipates achieving positive cash flow by early 2025.

Vivos Therapeutics reported Q2 2024 revenue of $4.1 million, up 19% both YoY and QoQ, driven by increased product sales and higher VIP enrollment revenue. Operating expenses decreased 31% YoY, marking eight consecutive quarters of cost reduction. Gross margin improved to 65% from 62% in Q2 2023, while operating loss reduced by 57% YoY.The company secured a strategic $7.5 million equity investment from New Seneca Partners and launched a new marketing and distribution model through alliances with medical sleep specialists. A pilot program demonstrated strong patient preference, with 79% of newly diagnosed OSA patients choosing Vivos' oral appliance therapy over alternatives.As of June 2024, Vivos has treated over 45,000 patients worldwide and trained more than 2,000 dentists. The company received Medicare reimbursement approval for its CARE devices and maintains $6.9 million in cash with $6.3 million in stockholders' equity. Management anticipates achieving positive cash flow by early 2025.